Piper Jaffray will host its 22nd annual Health Care Conference
November 30 - December 1 in New York. Industry participants and
investors will hear from more than 275 influential public and
private companies in the biotechnology, specialty pharmaceuticals,
drug discovery, medical technology, health care services, and
medical diagnostics and devices sectors.
“Piper Jaffray has a longstanding commitment to the health care
industry,” said Jeff Klinefelter, director of research at Piper
Jaffray. "Interest is particularly high in this year’s conference
given the macroeconomic environment and uncertainties associated
with pending changes to health care in America as legislated by
Congress.”
The 22nd annual Piper Jaffray Health Care Conference will
feature the industry’s leading senior management teams presenting
to an audience of nearly 1,500 attendees, including top
institutional investors, equity portfolio managers and research
analysts from the United States, Canada, the United Kingdom, Asia
and Europe.
Featured companies include: 3SBio Inc.; Abaxis Inc.; ABIOMED,
Inc.; AccessClosure, Inc.; Accuray Incorporated; Acorda
Therapeutics, Inc.; Addex Pharmaceuticals Sa; Advanced BioHealing,
Inc.; Advisory Board Co.; Affymax, Inc.; Affymetrix, Inc.; Agendia
B.V.; Agennix AG; Akorn Inc.; Albany Molecular Research Inc.; Alder
Biopharmaceuticals Inc.; Alexion Pharmaceuticals, Inc.; Algeta ASA;
ALGETA NO; Allergan Inc.; Alliance HealthCare Services; Allscripts
Healthcare Solutions, Inc.; Alnylam Pharmaceuticals, Inc.; Alphatec
Holdings, Inc.; Amedica Corporation; American Medical Systems
Holdings, Inc.; Anadys Pharmaceuticals, Inc.; AngioScore, Inc.;
AngioSlide, Ltd.; Animal Health International, Inc.; Anthera
Pharmaceuticals, Inc.; Antisoma plc; Ardea Biosciences; Arena
Pharmaceuticals, Inc.; Array BioPharma, Inc.; ArthroCare
Corporation; Athersys, Inc.; AtriCure, Inc.; Atritech, Inc.;
Avantis Medical Systems, Inc.; AVEO Pharmaceuticals, Inc.; BÂRRX
Medical, Inc.; Basilea Pharmaceutica; Baxter International Inc.;
Beckman Coulter, Inc.; Becton, Dickinson and Company;
Benefitfocus.com, Inc.; BioDelivery Sciences International Inc.;
BioHorizons, Inc.; BioMarin Pharmaceutical Inc.; bioMerieux;
BioScrip, Inc.; BioVex, Inc.; Boston Scientific Corporation;
Calistoga Pharmaceuticals, Inc.; Cameron Health, Inc.; CapSite;
Cardica Inc.; Cardiome Pharma Corp.; Celator Pharmaceuticals, Inc.;
Celgene Corporation; Cephalon, Inc.; Cepheid; Cerapedics, Inc.;
Cerner Corporation; Chimerix, Inc.; China Kanghui Holdings; China
Pharma Holdings, Inc.; Clinical Data, Inc.; CoAxia, Inc.; Computer
Programs And Systems Inc.; Concord Medical Services Holdings
Limited; CONMED Corporation; Constellation Pharmaceuticals, Inc.;
Corcept Therapeutics Inc.; Covance Inc.; Covidien, Ltd.; CryoLife,
Inc.; Curis Inc.; Cutera, Inc.; Cyberonics, Inc.; DexCom, Inc.;
Dfine, Inc.; Diversified Clinical Services, Inc.; DURECT
Corporation; DynaVox Inc.; E+ Healthcare, LLC; Enanta
Pharmaceuticals, Inc.; Endologix Inc.; Endosense SA; EndoStim Inc.;
Entellus Medical, Inc.; eResearchTechnology, Inc.; Exact Sciences
Corporation; Exelixis, Inc.; GenMark Diagnostics, Inc.; Genomic
Health, Inc.; Gen-Probe Incorporated; GI Dynamics, Inc.; Gilead
Sciences, Inc.; GlobeImmune, Inc.; Greatbatch, Inc.; GW
Pharmaceuticals; Hansen Medical, Inc.; Healthways, Inc.; HeartWare
International Inc.; Hill-Rom Holdings, Inc.; HMS Holdings Corp.;
Hospira Inc.; Hutchison MediPharma Ltd.; Ideal Image Development,
Inc.; IDev Technologies, Inc.; Illumina, Inc.; Immucor, Inc.; Impax
Laboratories, Inc.; Incyte Corporation; Infinity Pharmaceuticals,
Inc.; InfraReDx, Inc.; Integra LifeSciences Holdings Corporation;
IntegraMed America Inc.; Integrated Diagnostics Incorporated;
Intercell AG; InTouch Technologies, Inc.; Intuity Medical, Inc.;
IRIS International Inc.; iScience Interventional, Inc.; ISIS
Pharmaceuticals Inc.; Technologies, Inc.; Jarvik Heart, Inc.;
JenaValve Technology GmbH; Johnson & Johnson; K2M, Inc.;
Kinetic Concepts, Inc.; Laboratory Corporation of America Holdings;
LDR Holding Corporation; LipoScience Inc.; Lutonix Inc.;
MacroGenics, Inc.; MAKO Surgical Corp; Marina Biotech, Inc.; Masimo
Corporation; MedAssets, Inc.; Medidata Solutions, Inc.; Medivance,
Inc.; MELA Sciences, Inc.; Merit Medical Systems, Inc.; Merrimack
Pharmaceuticals, Inc.; Metabolex, Inc.; Micromet, Inc.; MicroPort
Medical (Shanghai) Co. Ltd.; Mindray Medical International Limited;
MonoSol Rx, Inc.; Morphosys AG; MWI Veterinary Supply, Inc.;
Myrexis, Inc.; Nanosphere, Inc.; Napo Pharmaceuticals, Inc.;
Neomend, Inc.; NeoVista, Inc.; Neurocrine Biosciences Inc.;
Neuronetics, Inc.; New American Therapeutics, Inc.; NovaMed, Inc.;
Novavax, Inc.; Novo Nordisk A/S; NuVasive, Inc.; Obagi Medical
Products, Inc.; Omeros Corporation; Omnicell, Inc.; Omthera
Pharmaceuticals, Inc.; OncoGenex Pharmaceuticals, Inc.; OpGen,
Inc.; OptiMedica Corporation; Optovue Inc.; Orthovita Inc.; Osiris
Therapeutics, Inc.; PAREXEL International Corporation;
PatientKeeper, Inc.; Patterson Companies Inc.; PDI, Inc.; Peregrine
Pharmaceuticals Inc.; Pharmaceutical Product Development, Inc.;
PharmaNet, Inc.; POZEN, Inc.; Precision Therapeutics, Inc.; Quality
Systems, Inc.; Reata Pharmaceuticals, Inc.; RedBrick Health
Corporation; Regado Biosciences, Inc.; Regeneron Pharmaceuticals
Inc.; Regulus Therapeutics, LLC; ResMed Inc.; Revance Therapeutics,
Inc.; Rib-X Pharmaceuticals, Inc.; Rigel Pharmaceuticals; Roche
Holding AG; Rockwell Medical Technologies Inc.; Salient Surgical
Technologies, Inc.; Salix Pharmaceuticals, Ltd.; Santarus Inc.;
SciClone Pharmaceuticals, Inc.; Seattle Genetics Inc.; SkinMedica,
Inc.; Somaxon Pharmaceuticals, Inc.; Sonitus Medical, Inc.; Sonoma
Orthopedic Products, Inc.; St. Jude Medical, Inc.; Stentys S.A.S.;
Steris Corp.; Stryker Corp.; Sucampo Pharmaceuticals, Inc.;
superDimension, Ltd.; Symetis SA; Symmetry Medical Inc.; TEI
Biosciences, Inc.; Tekmira Pharmaceuticals Corp.; Tengion, Inc.;
Tetraphase Pharmaceuticals, Inc.; Theravance Inc.; Thoratec
Corporation; Tolerx, Inc.; TomoTherapy Incorporated; TranS1 Inc.;
Trident USA Health Services; Trius Therapeutics, Inc.; TYRX, Inc.;
U.S. Preventive Medicine, Inc.; USGI Medical, Inc.; Valeant
Pharmaceuticals International; Vapotherm, Inc.; Varian Medical
Systems Inc.; Variation Biotechnologies, Inc.; VaxInnate, Inc.; VCA
Antech, Inc.; Vertex Pharmaceuticals Inc.; Vertos Medical, Inc.;
ViroPharma Inc.; Vital Images, Inc.; Volcano Corporation; Wright
Medical Group, Inc.; WuXi AppTec Inc.; XDx, Inc.; ZIOPHARM
Oncology, Inc.; ZONARE Medical Systems, Inc.
Company and investor participation in the Piper Jaffray Health
Care Conference is by invitation only. Clients interested in
attending should contact their Piper Jaffray representative.
General and research-related media inquiries should be directed to
AnalystMediaRelations@pjc.com. Investment banking-related media
inquiries should be directed to Carol Osnes at
carol.a.osnes@pjc.com.
About Piper Jaffray
Piper Jaffray Companies (NYSE: PJC) is a leading, international
investment bank and institutional securities firm, serving the
needs of corporations, private equity groups, public entities,
nonprofit clients and institutional investors. Founded in 1895,
Piper Jaffray provides a broad set of products and services,
including equity and debt capital markets products; public finance
services; financial advisory services; equity and fixed-income
institutional brokerage; equity research and fixed income
analytics; and asset management services. Piper Jaffray
headquarters are located in Minneapolis, Minnesota, with offices
across the U.S. and in London and Hong Kong. Piper Jaffray &
Co. is the firm's principal operating subsidiary.
(www.piperjaffray.com)
Since 1895. Member SIPC and FINRA.
© 2010 Piper Jaffray & Co., 800 Nicollet Mall, Suite 800,
Minneapolis, Minnesota 55402-7020
Piper Jaffray Companies (NYSE:PJC)
Historical Stock Chart
From Sep 2024 to Oct 2024
Piper Jaffray Companies (NYSE:PJC)
Historical Stock Chart
From Oct 2023 to Oct 2024